

Fig. 1




Fig. 2




Fig. 3




Fig. 4



Fig. 5




Fig. 6




Fig. 7

A

1 SIP-110 SSR-like region

catggaagactctttccgg

42 787

AGAAGTCATCCGGA

CCCTCCCATCCCTGGAGTCTCTGCAGAGGTTATT

TGACCAGCAGCTCTCCCCGGGCCTCCGTCCACG

874

TCCTCAGgtaaagggtcttgggggtgaaaagggtgagattaataccc

B

SIP110.exon1 1 - C G C C A C T A A C C T T T A T G T T C A C 24

s-SHP.exon1 1 G T T C C G A G T A G T T G T T A A A C T T T A D 25

SIP110.exon1 25 C T T T T - C C C T T C C C C C A A A A A 48

s-SHP.exon1 26 C T T T A A A C C T C T C T T G C C A A G G A A A T 50

SIP110.exon1 49 C A T C 73

s-SHP.exon1 51 C A T C A C C C C C C C C C C C C C C C C C C C 75

SIP110.exon1 74 T C T C T C C C C C C C C C C C C C C C C C C C 98

s-SHP.exon1 76 C T C T C 100


SIP110.exon1 99 A C 123

s-SHP.exon1 101 A C 125

SIP110.exon1 124 T C 130

s-SHP.exon1 126 A C 132

Fig. 8



1) Control SHIP

2) Control sSHIP
(non treated ES cells)

3) ES cell treated with negative control

4) ES cell treated with
shRNA against SHIP

5) ES cell treated with shRNA
against SHIP (EGFP marker)